Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Depreciation & Amortization (CF): 2013-2025

Historic Depreciation & Amortization (CF) for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to $966,000.

  • Coherus Oncology's Depreciation & Amortization (CF) fell 37.64% to $966,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year decrease of 23.46%. This contributed to the annual value of $5.3 million for FY2024, which is 39.17% up from last year.
  • As of Q3 2025, Coherus Oncology's Depreciation & Amortization (CF) stood at $966,000, which was down 4.92% from $1.0 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Depreciation & Amortization (CF) high stood at $1.5 million for Q3 2024, and its period low was $767,000 during Q1 2022.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $1.0 million (2024), whereas its average is $1.1 million.
  • Per our database at Business Quant, Coherus Oncology's Depreciation & Amortization (CF) spiked by 72.30% in 2024 and then slumped by 37.64% in 2025.
  • Coherus Oncology's Depreciation & Amortization (CF) (Quarterly) stood at $836,000 in 2021, then rose by 25.60% to $1.1 million in 2022, then grew by 1.24% to $1.1 million in 2023, then declined by 2.82% to $1.0 million in 2024, then slumped by 37.64% to $966,000 in 2025.
  • Its last three reported values are $966,000 in Q3 2025, $1.0 million for Q2 2025, and $1.0 million during Q1 2025.